Farglitazar
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
N-(o-benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine | |
| Clinical data | |
| Pregnancy category |
|
| Legal status |
|
| Identifiers | |
| CAS Number |
196808-45-4 |
| ATC code | None |
| PubChem | CID 170364 |
| IUPHAR/BPS | 2672 |
| ChemSpider |
148961 |
| UNII |
3433GY7132 |
| ChEMBL |
CHEMBL107367 |
| Chemical data | |
| Formula | C34H30N2O5 |
| Molar mass | 546.612 g/mol |
| |
| |
| | |
Farglitazar is a peroxisome proliferator-activated receptor agonist which is being developed by GlaxoSmithKline for the treatment of hepatic fibrosis. It is currently in phase II clinical trials.
References
This article is issued from Wikipedia - version of the Sunday, August 23, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
